Clinical Trial

Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

Study acronym: Arthritis
Recruiting
View on ClinicalTrials.gov →
Summary
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-09-20.
Trial Details
NCT Number NCT05062421
Lead Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions Arthritis, Rheumatoid
Enrollment 540 participants
Start Date 2021-04-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-11-17